stoxline Quote Chart Rank Option Currency Glossary
  
HOOKIPA Pharma Inc. (HOOK)
1.93  0.02 (1.05%)    02-06 10:47
Open: 1.9
High: 1.9641
Volume: 3,942
  
Pre. Close: 1.91
Low: 1.9
Market Cap: 19(M)
Technical analysis
2025-02-06 11:19:49 AM
Short term     
Mid term     
Targets 6-month :  2.78 1-year :  3.27
Resists First :  2.38 Second :  2.79
Pivot price 1.98
Supports First :  1.71 Second :  1.42
MAs MA(5) :  1.91 MA(20) :  1.96
MA(100) :  2.99 MA(250) :  5.32
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  27.5 D(3) :  30.4
RSI RSI(14): 42.9
52-week High :  10.5 Low :  1.71
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ HOOK ] has closed above bottom band by 23.3%. Bollinger Bands are 61.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.94 - 1.96 1.96 - 1.97
Low: 1.83 - 1.85 1.85 - 1.86
Close: 1.89 - 1.91 1.91 - 1.93
Company Description

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.

Headline News

Thu, 30 Jan 2025
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b - GlobeNewswire

Thu, 30 Jan 2025
Game-Changing HIV Vaccine Trial Fully Enrolled: HOOKIPA's Path to Potential Cure - StockTitan

Fri, 10 Jan 2025
Gilead Sciences Backs HOOKIPA-Poolbeg Merger Talks with $8.7M Funding Commitment - StockTitan

Wed, 08 Jan 2025
HOOKIPA Pharma Inc - FORM 8 (OPD) - GlobeNewswire

Wed, 08 Jan 2025
HOOKIPA Pharma Discloses Executive Stock Holdings, Awards Major RSU Grants to Leadership - StockTitan

Tue, 07 Jan 2025
Gilead Sciences Backs Poolbeg-HOOKIPA Merger as Fundraising Target Expands to $30M+ - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 10 (M)
Held by Insiders 6.95e+006 (%)
Held by Institutions 21.4 (%)
Shares Short 35 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -4.771e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin -93.2 %
Operating Margin -1 %
Return on Assets (ttm) 736.7 %
Return on Equity (ttm) -20.2 %
Qtrly Rev. Growth 5.216e+007 %
Gross Profit (p.s.) -62.41
Sales Per Share -59.03
EBITDA (p.s.) -3.9e+007
Qtrly Earnings Growth -3.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -74 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.04
Price to Cash Flow 0.21
Stock Dividends
Dividend 0
Forward Dividend 36240
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android